A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants with Prostate Cancer

Sponsor:

Janux Therapeutics

Sponsor Study ID:

PRCA-014-001

CTO #:

104306

NCT Number:

NCT07545811

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Prostate

Study Objectives:

To assess safety and tolerability of JANX014. To determine the maximum tolerated dose regimen (MTD-R) and/or maximally administered dose (MAD). To assess potential Phase 2 doses and determine a recommended Phase 2 dose regimen (RP2D-R).

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)